Navigation Links
Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

BASKING RIDGE, N.J., Jan. 6 /PRNewswire/ -- Regado Biosciences, Inc. announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2009, at 11:30am Pacific Time (2:30pm Eastern Time). Dr. Mazzo's presentation will include a review of the Company's lead compound in development, the REG1 System, its pipeline and enterprise-level business initiatives.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system is comprised of an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. This technology is being applied to acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect providing a safe and unique approach to personalized medicine.

Regado's lead program, the REG1 System, is comprised of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor and the second being its complementary reversal agent which can be used to completely or selectively lower the anticoagulant effects. The REG1 System is currently in Phase 2 clinical testing.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
2. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
3. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
4. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
5. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
6. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
8. Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System
9. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
10. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
11. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017   Instrument Business Outlook ( ... MN ) the 2016 Company of the ... newsletter tracking developments in the analytical and life ... consistently achieved outstanding technical, operational and financial results ... of IBO. "In 2016, Bio-Techne capitalized on opportunities ...
(Date:1/23/2017)...  Spherix Incorporated (Nasdaq: SPEX ) an ... technology and monetization of intellectual property, today provided an ... Anthony Hayes , Chief Executive Officer of Spherix, ... communicate with shareholders about the status of existing monetization ... other patent assets that fit with our current holdings.  ...
(Date:1/23/2017)... PA (PRWEB) , ... January 23, 2017 , ... ... Thomas has been appointed Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. ... of Madras in India. , Dr. Thomas’ career as an academic and ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific ... healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices in ... scientific consultants and contractors. This is the latest step in G&L’s expansion of ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/16/2016)... NEW YORK , Dec. 16, 2016 The global ... reach USD 12.14 billion by 2021 from USD 5.31 billion in ... ... market is mainly driven by technological advancements in medical devices, launch ... devices, rising preference for wireless connectivity among healthcare providers, and increasing ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):